
Twice-daily dosing of the oral JAK inhibitor deuruxolitinib nearly tripled response rates over once-daily dosing in severe alopecia areata.
Supplements and Featured Publications
This publication is sponsored by Novartis AG.
This Clinical Practice Brief provides an overview of the genetic cardiovascular risk biomarker lipoprotein a (Lp[a]), as well as its importance as an independent risk factor for cardiovascular disease, the prevalence of elevated Lp(a) levels among the global population, and recommendations for lipid management.






